PACB
Pacific Biosciences of California
NASDAQ: PACB · HEALTHCARE · MEDICAL DEVICES
$1.36
+3.16% today
Updated 2026-06-04
Market cap
$425.52M
P/E ratio
—
P/S ratio
2.66x
EPS (TTM)
$-0.41
Dividend yield
—
52W range
$1 – $3
Volume
6.4M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
4.7
Growth
C5.0
Quality
C+2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-6.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$2.46
+81.40%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy3 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z -6.38 — distress zone
- Thin margins at -80.30%
- Negative free cash flow $-47.73M
- Debt/equity 297.29x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $128.30M | $200.52M | $154.01M | $160.00M | $160.03M |
| Net income | $-314.25M | $-306.74M | $-309.85M | $-546.38M | $-8.28M |
| EPS | — | — | — | — | $-0.41 |
| Free cash flow | $-280.14M | $-275.39M | $-212.25M | $-113.92M | $-47.73M |
| Profit margin | -244.92% | -152.97% | -201.18% | -341.47% | -80.30% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-03 | VALANTINE, HANNAH | Buy | 223,492 | — |
| 2026-06-03 | SMITH, CHRISTOPHER M | Buy | 223,492 | — |
| 2026-06-03 | ORDONEZ, KATHY | Buy | 223,492 | — |
Peer comparison
Smart narrative
Pacific Biosciences of California trades at $1.36. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -6.38, it sits in the distress. TTM revenue stands at $160.03M. with profit margins at -80.30%.
Frequently asked questions
What is Pacific Biosciences of California's stock price?
Pacific Biosciences of California (PACB) trades at $1.36, on a P/S of 2.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Pacific Biosciences of California overvalued?
Pacific Biosciences of California carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Pacific Biosciences of California (PACB)?
The 12-month analyst consensus target is $2.46, about 81.4% above the current $1.36. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Pacific Biosciences of California's revenue?
Pacific Biosciences of California's trailing twelve-month revenue is $160.03M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Pacific Biosciences of California's Altman Z-Score is -6.38, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.66x
ROE-273.60%
Beta2.32
50D MA$1.45
200D MA$1.68
Shares out0.31B
Float0.30B
Short ratio—
Avg volume6.4M
Performance
1 week+0.00%
1 month+45.54%
3 months+22.56%
YTD-12.83%
1 year—
3 years—
5 years—